Search results
Author(s):
Irene Martín de Miguel
Added:
2 years ago
Did you know that atrial arrhythmias are the most common complication in adults with congenital heart disease?
Dr Irene Martin de Miguel (Adult Congenital Heart Disease Fellow at Mayo Clinic Rochester, US) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr Martinde Miguel provides an overview of the…
View more
Author(s):
A John Camm
Added:
3 years ago
Atrial fibrillation(AF), a major cause of morbidity and mortality in the Western world, is considered to be a rising epidemic.1–3 In the US alone, approximately 2.7 million people are affected by AF4 and this figure is projected to increase to an estimated 16 million by 2050.5 The rising prevalence of AF is mainly attributable to the ageing population6 and survival from other cardiovascular…
View more
Author(s):
Davide Cao
Added:
2 years ago
Dr Davide Cao (Icahn School of Medicine at Mount Sinai, US) discusses the key results and impact on clinical practice of the pre-specified analysis of the TWILIGHT trial presented at ESC Congress 2021.
TWILIGHT-HBR evaluated the effects of ticagrelor monotherapy versus ticagrelor (Brilinta) plus aspirin on bleeding and ischemic outcomes in a contemporary ARC-defined HBR population undergoing…
View more
Author(s):
Felicity Champney
Added:
5 years ago
Supporting the EP lab team - Tools and techniques for improved cyroablation procedural experience.
Felicity Champney RN
Filmed by Radcliffe Cardiology on site at EHRA 2018.
View more
Author(s):
Gregory Marcus
Added:
2 years ago
Dr Gregory Marcus (University of California, San Francisco, CA, US) shares the results from the HOLIDAY Monitors Trial. This study assessed how ethanol may trigger episodes of atrial fibrillation (AF).
Questions
What is the HOLIDAY Monitors Trial and what does it aim to address?
What was the study design, patient population and endpoints?
What are the main findings to date?
What conclusions can…
View more
Author(s):
Minh That Ton
,
Tri Huynh Quang Ho
,
Viet Lan Nguyen
,
et al
Added:
3 months ago
Author(s):
A Michael Lincoff
,
Harriette Van Spall
Added:
4 months ago
AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of…
View more
Author(s):
Maki Komiyama
,
Koji Hasegawa
Added:
3 years ago
Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has generated a pandemic that has heavily affected the global population, with more than 5.2 million infected and more than 337,000 deaths worldwide recorded between the end of 2019 and 24 May 2020.1 In the absence of vaccines or specific targeted treatments, strategies to…
View more
Author(s):
Kristian Rivera
,
Cristina Marzo
,
Nuria Sans
,
et al
Added:
3 years ago
Topic: 1. Clinical Cardiology
Introduction
Universal use of Direct Oral Anticoagulants (DOACs) in non-valvular atrial fibrillation (nVAF) is not possible for economic reasons. It is necessary to prescribe them to those patients with greater potential benefit. The best way to achieve this objective is the application of a territorial protocol, designed and accepted by all professionals…
View more
Author(s):
Paulus Kirchhof
Added:
1 year ago
In this video interview from EHRA 2022, Dr Paulus Kirchhof (University Heart Center Hamburg, Hamburg, DE) discusses the outcomes of the EAST-AFNET 4 Study, and the applicability of these findings in clinical practice.
Discussion points:
An outline of the EAST-AFNET 4 Study
Benefits of early AF treatment
Observations from clinical practice
Take-home messages
Further research required
…
View more